Tumor cells express membrane-bound complement regulatory proteins (mCRP; CD35, CD46, CD55, and CD59) that normal cells use to prevent excessive activation of complement cascades in the early stages of an immune response [52,53]. This evidence concerns the gene CD59 and neoplasm.